Main
>
ONCOLOGY (**)
>
Lung>NSCLC>EGFR+>MET>***
>
Treatment
>
Co: UK. A. Osimertinib
>
(*) USA 2nd Line OK: 2017. 03.30.
(*) USA 2nd Line OK: 2017. 03.30.'s products
This section has no products